CINECA IRIS Institutional Research Information System

CLERICO, Marinella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.230
EU - Europa 6.555
AS - Asia 2.474
AF - Africa 232
SA - Sud America 77
Continente sconosciuto - Info sul continente non disponibili 47
OC - Oceania 40
Totale 17.655
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.097
IT - Italia 1.292
CN - Cina 1.145
DE - Germania 863
IE - Irlanda 833
SE - Svezia 761
UA - Ucraina 550
FR - Francia 506
FI - Finlandia 391
GB - Regno Unito 361
KR - Corea 347
SG - Singapore 319
VN - Vietnam 212
AT - Austria 207
PL - Polonia 170
SN - Senegal 142
ES - Italia 130
DK - Danimarca 118
IN - India 110
CA - Canada 108
JP - Giappone 106
NL - Olanda 87
GR - Grecia 65
BE - Belgio 53
TR - Turchia 49
EU - Europa 44
HK - Hong Kong 42
BR - Brasile 41
MU - Mauritius 38
IR - Iran 37
RU - Federazione Russa 37
AU - Australia 29
CH - Svizzera 24
MX - Messico 20
RO - Romania 20
NO - Norvegia 18
EG - Egitto 17
SA - Arabia Saudita 17
IL - Israele 16
PT - Portogallo 15
CZ - Repubblica Ceca 14
UZ - Uzbekistan 14
CO - Colombia 13
ID - Indonesia 13
TW - Taiwan 13
NG - Nigeria 12
NZ - Nuova Zelanda 11
AR - Argentina 9
TH - Thailandia 8
CI - Costa d'Avorio 7
PH - Filippine 7
RS - Serbia 7
ZA - Sudafrica 7
MK - Macedonia 6
BG - Bulgaria 5
LB - Libano 5
MA - Marocco 5
UY - Uruguay 5
CL - Cile 4
LT - Lituania 4
SI - Slovenia 4
BY - Bielorussia 3
EE - Estonia 3
MY - Malesia 3
PE - Perù 3
PK - Pakistan 3
EC - Ecuador 2
GP - Guadalupe 2
HU - Ungheria 2
LU - Lussemburgo 2
OM - Oman 2
SK - Slovacchia (Repubblica Slovacca) 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AP - ???statistics.table.value.countryCode.AP??? 1
BD - Bangladesh 1
CR - Costa Rica 1
CU - Cuba 1
CY - Cipro 1
DM - Dominica 1
DZ - Algeria 1
HR - Croazia 1
IQ - Iraq 1
KW - Kuwait 1
MD - Moldavia 1
NP - Nepal 1
QA - Qatar 1
SC - Seychelles 1
TN - Tunisia 1
ZW - Zimbabwe 1
Totale 17.655
Salva come PNG Salva come JPEG
Città #
Chandler 1.316
Dublin 815
Beijing 713
Ann Arbor 564
Fairfield 376
Jacksonville 346
Ashburn 342
Houston 337
Medford 306
Fremont 282
Nyköping 270
Torino 264
Princeton 263
Villeurbanne 251
Wilmington 247
Dearborn 220
Vienna 205
Woodbridge 194
Singapore 175
Warsaw 160
Milan 155
Dong Ket 145
Cambridge 120
Seattle 118
Redwood City 108
Turin 101
Boston 86
Boardman 71
Pisa 55
Madrid 53
New York 49
Verona 49
Rome 47
Guangzhou 45
San Diego 38
Washington 37
Hangzhou 36
Toronto 36
Brussels 35
Norwalk 35
Falls Church 34
Tokyo 31
London 30
Nanjing 30
Chengdu 27
Hefei 26
San Mateo 26
Shanghai 26
Paris 25
Groningen 24
Seoul 24
Helsinki 23
Istanbul 20
Lachine 20
Los Angeles 20
Pune 20
Düsseldorf 19
Jinan 19
Seongnam 19
Hong Kong 18
Naples 18
Menlo Park 17
Duncan 16
Nürnberg 16
Southampton 16
Athens 14
Chicago 14
Dallas 14
Kunming 14
Mountain View 14
Redhill 14
Zhengzhou 14
Central District 13
Nanchang 13
Barcelona 12
Genova 12
Berlin 11
Durham 11
Fuzhou 11
Hebei 11
Lappeenranta 11
Munich 11
Ottawa 11
Taipei 11
Upper Marlboro 11
Abuja 10
Bologna 10
Moncalieri 10
Redmond 10
Salt Lake City 10
Amsterdam 9
Bochum 9
Bucharest 9
Frankfurt am Main 9
Palermo 9
Portland 9
Florence 8
Hanoi 8
Manchester 8
San Francisco 8
Totale 10.012
Salva come PNG Salva come JPEG
Nome #
Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study 592
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML 452
Randomized trial of thymectomy in myasthenia gravis 419
Pregnancy epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis 375
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 348
Computer assisted interactive learning in medical education: flipped classrooms of clinical neurology for medicine students 315
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis 306
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study 216
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis 181
Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: Findings from an Italian independent registry 179
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 177
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 166
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 166
D-dimer Increasing After First Alemtuzumab Administration in a Multiple Sclerosis Patient 160
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study 149
In Human Multiple sclerosis, T helper 17 lymphocytes display increased levels of JAK2 that stabilize cell surface IFN-YR2chain 146
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment 143
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses 135
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. 132
The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View 130
Natalizumab in Multiple Sclerosis: Long-Term Management 129
CHARACTERIZATION OF AUTOREACTIVE TCR REPERTOIRE IN PATIENTS AFFECTED BYMULTIPLE SCLEROSIS. 125
Influence of cigarette smoking on ALS outcome: A population-based study 123
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report 122
Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail 122
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. 118
Telemedicine and the challenge of epilepsy management at the time of COVID-19 pandemic 118
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 111
Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosis 110
T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta 109
Treatment response to interferon beta: Biological (MxA protein or IL-10 mRNA level) or MRI indicators? 106
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab 103
Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP 101
Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question 101
Computational modeling of the immune response in multiple sclerosis using epimod framework 101
Are arterial hypertension and diabetes modifiers of ALS phenotype and outcome? A population-based study 99
To switch therapies in RRMS: why and when? A real-life multicentre study 94
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis 93
Dementia care and COVID-19 pandemic: a necessary digital revolution 92
Online Validation of a Battery of Questionnaires for the Assessment of Family Functioning and Related Factors 89
The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders 88
T HELPER 22 CELLS INCREASE IN MULTIPLE SCELROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 88
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea 88
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b 87
Circulating T helper 22 cells increase in multiple sclerosis patients:phenotypical and functional characterization. 86
TYPE 1 INTERFERON RECEPTOR (IFNA-R1). EXPRESSING TH17 LYMPHOCYTES ARE INCREASED DURING MS RELAPSES AND ARE SELECTIVELY INTHBITED BY IFNβ 83
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study 83
Epigenetic therapy for Friedreich ataxia. 82
Early weight loss in amyotrophic lateral sclerosis: Outcome relevance and clinical correlates in a population-based cohort 82
Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study 82
Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation 81
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 81
Estrogen receptor alpha in peripheral blood lymphocytes of multiple sclerosis patients: a pivotal study of its role in pregnant patients 81
A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b 80
Estrogen receptor alpha role in multiple sclerosis patients: trying to identify a new biomarker of disease activity 80
Cytokine and Chemokine mRNA in Peripheral Blood of MS Patients Correlates with Treatment response and Interferon Beta Dose 79
Comparison of immunomodulatory treatments for multiple sclerosis. 78
Estrogen Receptor Alpha- Associated Genomic Regions Are Potential Core of T Cell Subtypes Identity 77
Fake news, influencers and health-related professional participation on the Web: A pilot study on a social-network of people with Multiple Sclerosis 77
Associations between socioemotional alterations, quality of life, and social functioning in multiple sclerosis: A scoping review 77
T HELPER 22 CELLS INCREASE IN MULTIPLE SCLEROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 76
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials 76
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 76
Correlation of anti-interferon beta neutralising antobodies with clinical response and mri activity in the INCOMIN (independent comparison of interferon) trial. 75
Prognostic influence of pre-morbid smoking habits, diabetes, arterial hypertension and vascular risk profile on phenotype and outcome of ALS patients: a population-based study. 75
Estrogen receptor-alpha regulates epigenetic changes on genomic regulatory regions: potential biomarkers in multiple sclerosis outcomes 75
Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD). 74
Is the combination of different treatment responseindicators useful to identify patients with a sub-optimal response to interferon beta? 74
Cytokines and Chemokine mRNA in perpheral blood of multiple sclerosis patients correlates with treatment response and interferon beta dose 74
Estrogen receptor alpha regulates key genomic regions of t-helper 17 and T-regulatory cells in Multiple Sclerosis: a new potential biomarker of disease activity. 74
Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients. 73
T helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β 73
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function 73
Comorbidities affect treatment choice and persistence in RRMS: a real-life multicenter study 73
Th17, an effector T Lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon beta 72
Estrogen Receptor Alpha Regulates Key Genomic Regions of Thelper 17 and T Regulatory Cells in Multiple Sclerosis: A New Potential Biomarker of Disease Activity 72
Epigenetic signature in T helper 17 and regulatory T cells in multiple sclerosis patients during pregnancy 72
La dose ottimale di interferone beta: studio preliminare sulla tolleranza della dose di 375 microgrammi di interferone beta-1b 71
Treatment response indicators in multiple sclerosis. Persistence of mri activity during first months of immune-modulating drug treatment is predictive of persistence of clinical disease activity over the long term 70
T-helper 17 lymphocytes during MS relapses: antigen specificity and cytokine production. A multicentre longitunal study 70
Botulinum toxin A (Dysport) for treatment of sialorrhea in patients with neurologic disorders. 70
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient 70
Autoimmunity profile in interferon beta- 1a treated multiple sclerosis patients. the auprin study: comparision of 2 different dosage of subcutaneous interferon-beta 1a. 69
can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis? 69
Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis. 69
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation 69
Atypical presentation of superficial sclerosis successfully treated with iron chelation 68
Prophylaxis of chronic migraine with OnabotulinumtoxinA: experience and evidence in clinical practice 68
Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study 68
A COCHRANE meta-analysis on the efficacy of recombinant interferon beta in preventing conversion of clinically isolated syndromes 67
To prevent conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane Metanalysis 67
Clinically isolated syndrome: when to treat? A Cochrane analysis 67
Adherence to interferon-beta treatment and results of therapy switching 67
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia 67
The Use of Social Media and Digital Devices Among Italian Neurologists 67
A COCHRANE review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to Multiple Sclerosis 66
Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a 66
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study. 65
Assessing treatment response to immunomodulatory drugs for ms: a single active mri scan after 6 months of treatment is the best indicator of persisting disease activity 65
T-helper (Th) 22, a newly identified lymphocyte subset, increases 1-3 months before an MS relapse and it is not sensitive to INF beta 65
Totale 11.510
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.712
article - articoli 0
book - libri 0
conference - conferenze 29.886
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.598
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.294 86 105 190 286 173 304 248 144 228 259 135 136
2020/20212.530 239 130 180 317 204 164 137 111 339 175 179 355
2021/20222.812 76 67 104 173 147 161 170 161 146 330 556 721
2022/20234.013 416 322 135 406 332 998 300 235 390 135 209 135
2023/20241.960 212 299 119 125 140 243 85 124 12 143 154 304
2024/202560 60 0 0 0 0 0 0 0 0 0 0 0
Totale 18.435